ATE240113T1 - Behandlung von infarkten durch inhibierung von nf-kappab - Google Patents

Behandlung von infarkten durch inhibierung von nf-kappab

Info

Publication number
ATE240113T1
ATE240113T1 AT98906511T AT98906511T ATE240113T1 AT E240113 T1 ATE240113 T1 AT E240113T1 AT 98906511 T AT98906511 T AT 98906511T AT 98906511 T AT98906511 T AT 98906511T AT E240113 T1 ATE240113 T1 AT E240113T1
Authority
AT
Austria
Prior art keywords
kappab
infarcts
inhibiting
treatment
ubiquitin
Prior art date
Application number
AT98906511T
Other languages
German (de)
English (en)
Inventor
Stephen Brand
Alfred L Goldberg
Louis Plamondon
Francois Soucy
Peter J Elliot
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE240113T1 publication Critical patent/ATE240113T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Organic Insulating Materials (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Artificial Filaments (AREA)
  • Transplanting Machines (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
AT98906511T 1997-02-15 1998-02-17 Behandlung von infarkten durch inhibierung von nf-kappab ATE240113T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80193697A 1997-02-15 1997-02-15
US98833997A 1997-12-03 1997-12-03
PCT/US1998/003077 WO1998035691A1 (en) 1997-02-15 1998-02-17 Treatment of infarcts through inhibition of nf-kappab

Publications (1)

Publication Number Publication Date
ATE240113T1 true ATE240113T1 (de) 2003-05-15

Family

ID=27122399

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906511T ATE240113T1 (de) 1997-02-15 1998-02-17 Behandlung von infarkten durch inhibierung von nf-kappab

Country Status (14)

Country Link
US (3) US6271199B2 (https=)
EP (1) EP0979096B1 (https=)
JP (1) JP2001511814A (https=)
CN (1) CN1159061C (https=)
AT (1) ATE240113T1 (https=)
AU (1) AU741802B2 (https=)
CA (1) CA2281224A1 (https=)
DE (1) DE69814618T2 (https=)
ES (1) ES2196547T3 (https=)
IL (1) IL131410A0 (https=)
NO (1) NO321203B1 (https=)
NZ (1) NZ337364A (https=)
PT (1) PT979096E (https=)
WO (1) WO1998035691A1 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4215219B2 (ja) * 1997-07-04 2009-01-28 アンジェスＭｇ株式会社 脳保護剤
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US20090042807A1 (en) * 1998-05-20 2009-02-12 Nisar Ahmed Khan Oligopeptide treatment of ischemia reperfusion injury
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1223948A2 (en) * 1999-09-13 2002-07-24 CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
CA2429163C (en) * 2000-11-16 2013-02-12 The Regents Of The University Of California Marine actinomycete taxon for drug fermentation and product discovery
JP4162491B2 (ja) 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6740674B2 (en) 2001-05-21 2004-05-25 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
ATE502642T1 (de) * 2001-10-05 2011-04-15 Zalicus Inc Kombinationen für die behandlung von immun- entzündlichen erkrankungen
ATE517617T1 (de) * 2001-12-10 2011-08-15 Yansheng Dr Du Behandlung von parkinson erkrankung mit kape
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
AU2004253478A1 (en) * 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
US7348305B2 (en) 2003-08-28 2008-03-25 Department Of Veterans Affairs, Rehabilitation Inhibitor of cardiac tachyarrhythmias
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
SE0400399D0 (sv) * 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP2266988A1 (en) 2004-04-30 2010-12-29 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7425580B2 (en) * 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
EP1771194A2 (en) * 2004-07-07 2007-04-11 Biodevelops Pharma Entwicklung GmbH Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface
US20060008454A1 (en) * 2004-07-07 2006-01-12 Dr. Helmut Brunar Use of a compound for enhancing the expression of membrane proteins on the cell surface
US20090191105A1 (en) * 2004-08-30 2009-07-30 Kazuhiro Tanahashi Fractionation Apparatus
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
EP1830838B1 (en) 2004-12-03 2012-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplastic diseases
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
EP1912664A2 (en) * 2005-07-06 2008-04-23 Biodevelops Pharma Entwicklung GmbH Use of a compound for enhancing the expression of membrane proteins on the cell surface
WO2007011757A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
US7691896B2 (en) * 2005-08-10 2010-04-06 President And Fellows Of Harvard College Analogs of salinosporamide A
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
ES2293834B1 (es) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
WO2009140287A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
CA2727862C (en) 2008-06-17 2016-04-19 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
EP2527434B1 (en) 2010-01-22 2017-08-09 Japan Science and Technology Agency Probe reagent for measurement of proteolytic activity
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
CN108498532B (zh) 2012-05-09 2021-07-23 坎泰克斯制药股份有限公司 骨髓抑制的治疗
IN2013MU01431A (https=) 2013-04-16 2015-06-26 Cipla Ltd
EP3102585B1 (en) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
TN2016000492A1 (en) 2014-05-20 2018-04-04 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy.
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
JP2018510859A (ja) 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子
US11897969B2 (en) 2017-10-26 2024-02-13 The Regents Of The University Of California Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661270B2 (en) 1990-03-05 1995-07-20 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
EP0824918B1 (en) * 1995-05-12 2007-03-28 AnGes MG, Inc. REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB
US5942494A (en) 1995-10-06 1999-08-24 The Trustees Of Columbia University In The City Of New York Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70)
JP2000510328A (ja) 1996-03-19 2000-08-15 プロスクリプト・インコーポレイテッド ＩкＢαを部位特異的にリン酸化し得るキナーゼ
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof

Also Published As

Publication number Publication date
CA2281224A1 (en) 1998-08-20
US20030069189A1 (en) 2003-04-10
AU741802B2 (en) 2001-12-13
ES2196547T3 (es) 2003-12-16
US20010053760A1 (en) 2001-12-20
PT979096E (pt) 2003-09-30
NO993935L (no) 1999-10-04
EP0979096B1 (en) 2003-05-14
NO993935D0 (no) 1999-08-16
US20010002391A1 (en) 2001-05-31
CN1250376A (zh) 2000-04-12
NO321203B1 (no) 2006-04-03
NZ337364A (en) 2001-06-29
HK1025266A1 (en) 2000-11-10
US6271199B2 (en) 2001-08-07
DE69814618D1 (de) 2003-06-18
WO1998035691A1 (en) 1998-08-20
AU6171998A (en) 1998-09-08
DE69814618T2 (de) 2004-03-25
IL131410A0 (en) 2001-01-28
CN1159061C (zh) 2004-07-28
JP2001511814A (ja) 2001-08-14
EP0979096A1 (en) 2000-02-16

Similar Documents

Publication Publication Date Title
ATE240113T1 (de) Behandlung von infarkten durch inhibierung von nf-kappab
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DE69830751D1 (de) Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen
ATE199552T1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
DE69807115D1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
ATE271041T1 (de) Analoga von duocarmycin and cc-1065
EP0677048A1 (en) CYCLIC SULPHONES AS INHIBITORS RETROVIRAL PROTEASES.
AP9200410A0 (en) Retroviral protease inhibitors.
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
ATE250574T1 (de) Neue verbindungen
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
DK0934065T3 (da) Hidtil ukendte cruptophycinderivater som antieoplastiske midler
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
BR9808299A (pt) O uso de levobupivacaìna ou ropivacaìna para o tratamento da enxaqueca
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
TR200101568T2 (tr) Sülfonamid bileşimleri ve bunların ilaç olarak kullanımları
ATE333277T1 (de) Behandlung von dyskinesie
DE59813914D1 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
DE69930844D1 (de) Inhibitoren von mycobakterien
DK1042288T3 (da) Tripeptidyl-peptidase inhibitorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0979096

Country of ref document: EP

REN Ceased due to non-payment of the annual fee